CalciMedica, Inc. (NASDAQ:CALC) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC lifted its position in shares of CalciMedica, Inc. (NASDAQ:CALC) by 51.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 66,553 shares of the company’s stock after buying an additional 22,525 shares during the period. Geode Capital Management LLC owned approximately 0.62% of CalciMedica worth $295,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, Atria Investments Inc increased its holdings in CalciMedica by 136.5% in the 3rd quarter. Atria Investments Inc now owns 26,503 shares of the company’s stock valued at $117,000 after purchasing an additional 15,296 shares during the last quarter.

CalciMedica Stock Performance

CalciMedica stock opened at $2.90 on Tuesday. CalciMedica, Inc. has a fifty-two week low of $2.05 and a fifty-two week high of $8.38. The firm has a 50 day moving average price of $3.16 and a 200 day moving average price of $3.89. The company has a market capitalization of $39.10 million, a PE ratio of -2.69 and a beta of 1.22.

Insider Activity at CalciMedica

In other CalciMedica news, Director Fred A. Middleton purchased 87,744 shares of the firm’s stock in a transaction on Friday, November 1st. The stock was bought at an average price of $3.75 per share, with a total value of $329,040.00. Following the transaction, the director now directly owns 814,300 shares of the company’s stock, valued at approximately $3,053,625. This represents a 12.08 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO A. Rachel Leheny purchased 20,000 shares of the firm’s stock in a transaction on Friday, November 1st. The stock was acquired at an average cost of $3.75 per share, with a total value of $75,000.00. Following the transaction, the chief executive officer now directly owns 130,926 shares in the company, valued at $490,972.50. This trade represents a 18.03 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 252,744 shares of company stock worth $942,510. Insiders own 41.55% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of CalciMedica in a report on Thursday, November 14th.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.